Zevra Therapeutics (ZVRA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Zevra Therapeutics

NasdaqGS•Healthcare•Biotechnology

$12.68+0.28(0.02%)Pre-market

Market Cap

$700.41M

P/E

12.0x

P/S

5.1x

P/B

3.2x

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

How this company scores

GoodMetricSide Score: 74/100

Strongest: Profitability (22/25); weakest: Cash & Earnings Quality (15/25).

Profitability22/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality15/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.0x5y range 4.1x – 182.5x

Currently near its 5-quarter median.

P/S · 5.1x5y range 4.2x – 20.2x

Currently below its 20-quarter median.

P/B · 3.2x5y range 1.5x – 9.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $700.41M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $136.07M
Q. Revenue: $39.66M
TTM EBITDA: $85.91M
TTM Op. Income: $82.38M
Q. Op. Income: $16.78M
TTM Net Income: $58.26M
Q. Net Income: $8.75M
EPS: $0.14
Shares Out.: $59.16M

$136.07M in TTM revenue grew 119.4% YoY, reaching $39.66M last quarter. TTM EBITDA of $85.91M and TTM operating income of $82.38M show growth is flowing through to the bottom line. TTM net income of $58.26M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 43.2%
Op. Margin: 42.3%
Net Margin: 22.1%

Op. margin of 42.3% is up 316.8% YoY — cost efficiency is improving. Net margin at 22.1% Over the past year, operating margin is up 115% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 12.0x
P/S Ratio: 5.1x
P/B Ratio: 3.2x

At 12.0x P/E, the stock trades below typical market levels. P/S of 5.1x and P/B of 3.2x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 93% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $302.71M
Cash: $145.32M
Long-Term Debt: N/A
Book Value: $217.65M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $17.03M
TTM Free Cash Flow: $32.62M
FCF Margin: 24.0%
FCF / Net Income: 0.6

TTM FCF of $32.62M on $17.03M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 6 consecutive quarters — an improving trend.